 CAMBRIDGE, Mass., March 10, 2021 GLOBE NEWSWIRE -- Checkmate Pharmaceuticals, Inc. NASDAQ: CMPI Checkmate, a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that it will present new translational data at the 2021 American Association for Cancer Research AACR Annual Meeting taking place virtually from April 10-15, 2021. Data from Checkmates Phase 1b trial of CMP-001 in subjects with advanced melanoma will be presented in an oral presentation during the Clinical Trials with Novel Immuno-oncology Strategies Session. 